These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36293083)

  • 21. Citrate dose for continuous hemofiltration: effect on calcium and magnesium balance, parathormone and vitamin D status, a randomized controlled trial.
    Boer W; Fivez T; Vander Laenen M; Bruckers L; Grön HJ; Schetz M; Oudemans-van Straaten H
    BMC Nephrol; 2021 Dec; 22(1):409. PubMed ID: 34895160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modes of Degradation and Impurity Characterization in rhPTH (1-34) during Stability Studies.
    Kothari R; Kumar V; Jena R; Tunga R; Tunga BS
    PDA J Pharm Sci Technol; 2011; 65(4):348-62. PubMed ID: 22293522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
    Pazianas M; Miller PD
    J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
    Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parathyroid hormone measurement in chronic kidney disease: Impact of inter-method variability on mineral bone disease assessment.
    White CA; Sarabia S; Collier CP; McCudden C; Holden RM
    Clin Biochem; 2021 Aug; 94():62-66. PubMed ID: 33895125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship of parathyroid hormone: relative sensitivity of rabbit renal microvessel and tubule adenylate cyclases to oxidized PTH and PTH inhibitors.
    Helwig JJ; Yang MC; Bollack C; Judes C; Pang PK
    Eur J Pharmacol; 1987 Aug; 140(3):247-57. PubMed ID: 2820761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parathyroid hormone metabolism and signaling in health and chronic kidney disease.
    Evenepoel P; Bover J; Ureña Torres P
    Kidney Int; 2016 Dec; 90(6):1184-1190. PubMed ID: 27653840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation.
    Gao P; D'Amour P
    Clin Lab; 2005; 51(1-2):21-9. PubMed ID: 15719701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.
    Kritmetapak K; Pongchaiyakul C
    Int J Nephrol; 2019; 2019():5496710. PubMed ID: 31637056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidized forms of parathyroid hormone with biological activity. Separation and characterization of hormone forms oxidized at methionine 8 and methionine 18.
    Frelinger AL; Zull JE
    J Biol Chem; 1984 May; 259(9):5507-13. PubMed ID: 6715358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
    Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
    Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of biological effects of oxidized parathyroid hormone-(1-34) in dogs and rats.
    Galceran T; Lewis-Finch J; Martin KJ; Slatopolsky E
    Endocrinology; 1984 Dec; 115(6):2375-8. PubMed ID: 6499771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts.
    Huang MS; Morony S; Lu J; Zhang Z; Bezouglaia O; Tseng W; Tetradis S; Demer LL; Tintut Y
    J Biol Chem; 2007 Jul; 282(29):21237-43. PubMed ID: 17522049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.
    Geng S; Kuang Z; Peissig PL; Page D; Maursetter L; Hansen KE
    Osteoporos Int; 2019 Oct; 30(10):2019-2025. PubMed ID: 31190122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling.
    Pawlak K; Sieklucka B; Pawlak D
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia.
    Znorko B; Pawlak D; Oksztulska-Kolanek E; Domaniewski T; Pryczynicz A; Roszczenko A; Rogalska J; Lipowicz P; Doroszko M; Brzoska MM; Pawlak K
    Cytokine; 2018 Jun; 106():19-28. PubMed ID: 29529595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-129 Blocks Secondary Hyperparathyroidism-Inducing Fgf23/αKlotho Signaling in Mice with Chronic Kidney Disease.
    Xu M; Li H; Bai Y; He J; Chen R; An N; Li Y; Dong Y
    Am J Med Sci; 2021 May; 361(5):624-634. PubMed ID: 33781552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.